Nationwide retrospective study of critically ill adults with sickle cell disease in France.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
30 11 2021
Historique:
received: 16 07 2021
accepted: 15 11 2021
entrez: 1 12 2021
pubmed: 2 12 2021
medline: 15 2 2022
Statut: epublish

Résumé

Little is known about patients with sickle cell disease (SCD) who require intensive care unit (ICU) admission. The goals of this study were to assess outcomes in patients admitted to the ICU for acute complications of SCD and to identify factors associated with adverse outcomes. This multicenter retrospective study included consecutive adults with SCD admitted to one of 17 participating ICUs. An adverse outcome was defined as death or a need for life-sustaining therapies (non-invasive or invasive ventilation, vasoactive drugs, renal replacement therapy, and/or extracorporeal membrane oxygenation). Factors associated with adverse outcomes were identified by mixed multivariable logistic regression. We included 488 patients admitted in 2015-2017. The main reasons for ICU admission were acute chest syndrome (47.5%) and severely painful vaso-occlusive event (21.3%). Sixteen (3.3%) patients died in the ICU, mainly of multi-organ failure following a painful vaso-occlusive event or sepsis. An adverse outcome occurred in 81 (16.6%; 95% confidence interval [95% CI], 13.3%-19.9%) patients. Independent factors associated with adverse outcomes were low mean arterial blood pressure (adjusted odds ratio [aOR], 0.98; 95% CI 0.95-0.99; p = 0.027), faster respiratory rate (aOR, 1.09; 95% CI 1.05-1.14; p < 0.0001), higher haemoglobin level (aOR, 1.22; 95% CI 1.01-1.48; p = 0.038), impaired creatinine clearance at ICU admission (aOR, 0.98; 95% CI 0.97-0.98; p < 0.0001), and red blood cell exchange before ICU admission (aOR, 5.16; 95% CI 1.16-22.94; p = 0.031). Patients with SCD have a substantial risk of adverse outcomes if they require ICU admission. Early ICU admission should be encouraged in patients who develop abnormal physiological parameters.

Identifiants

pubmed: 34848756
doi: 10.1038/s41598-021-02437-2
pii: 10.1038/s41598-021-02437-2
pmc: PMC8632921
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

23132

Informations de copyright

© 2021. The Author(s).

Références

JAMA. 2014 Sep 10;312(10):1033-48
pubmed: 25203083
Nephron Clin Pract. 2012;120(4):c179-84
pubmed: 22890468
N Engl J Med. 1980 May 1;302(18):992-5
pubmed: 7366623
Sultan Qaboos Univ Med J. 2012 May;12(2):177-83
pubmed: 22548136
Pediatr Blood Cancer. 2009 Apr;52(4):481-5
pubmed: 19058209
JAMA. 2010 Apr 7;303(13):1288-94
pubmed: 20371788
N Engl J Med. 2017 Feb 2;376(5):429-439
pubmed: 27959701
Ann Emerg Med. 1996 Mar;27(3):305-8
pubmed: 8599488
Scand J Clin Lab Invest. 2007;67(1):39-69
pubmed: 17365984
Am J Respir Crit Care Med. 2008 Mar 15;177(6):646-53
pubmed: 18174543
JAMA Netw Open. 2021 Jan 4;4(1):e2034004
pubmed: 33443583
Am J Hematol. 2015 Mar;90(3):215-9
pubmed: 25469750
Intensive Care Med. 2020 Dec;46(12):2238-2247
pubmed: 32901374
Rev Med Interne. 2009 Sep;30 Suppl 3:S162-223
pubmed: 19713011
Br J Haematol. 2003 Oct;123(2):359-65
pubmed: 14531921
Intensive Care Med. 2017 Jan;43(1):80-82
pubmed: 27492270
J Matern Fetal Neonatal Med. 2018 Feb;31(4):525-529
pubmed: 28142291
BMC Nephrol. 2012 Aug 06;13:83
pubmed: 22866669
Lancet. 2017 Jul 15;390(10091):311-323
pubmed: 28159390
Blood. 1997 Mar 1;89(5):1533-42
pubmed: 9057634
J Intensive Care Med. 2022 Jan;37(1):100-106
pubmed: 33307945
N Engl J Med. 1994 Jun 9;330(23):1639-44
pubmed: 7993409
Mediterr J Hematol Infect Dis. 2018 May 01;10(1):e2018032
pubmed: 29755709
N Engl J Med. 2018 Jul 19;379(3):226-235
pubmed: 30021096
Crit Care Med. 2014 Jul;42(7):1629-39
pubmed: 24674925
Blood. 2016 Sep 8;128(10):1436-8
pubmed: 27439910
J Crit Care. 2017 Dec;42:238-242
pubmed: 28797896
Rev Med Interne. 2015 May 11;36(5 Suppl 1):5S3-84
pubmed: 26007619
Hematol J. 2002;3(1):56-60
pubmed: 11960397

Auteurs

Maïté Agbakou (M)

Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire Hôtel-Dieu, 30 Bd. Jean Monnet, 44093, Nantes Cedex 1, France.

Armand Mekontso-Dessap (A)

Médecine Intensive Réanimation, Hôpital Henri Mondor, Assistance Publique des Hôpitaux de Paris, Créteil, France.

Morgane Pere (M)

Plateforme de methodologie et biostatistique, Direction de la Recherche de l'Innovation, Centre Hospitalier Universitaire de Nantes, Nantes, France.

Guillaume Voiriot (G)

Sorbonne Université, Assistance Publique Hôpitaux de Paris, Service de Médecine Intensive et Réanimation, Hôpital Tenon, Paris, France.

Muriel Picard (M)

Réanimation Polyvalente, Institut Universitaire du Cancer de Toulouse-Oncopole, CHU Toulouse, Toulouse, France.

Jérémy Bourenne (J)

Médecine Intensive Réanimation, Réanimation des Urgences, CHU la Timone 2, Marseille, France.

Stephan Ehrmann (S)

Médecine Intensive Réanimation, INSERM CIC 1415, CRICS-TriggerSEP Research Network, Centre Hospitalier Régional Universitaire de Tours and Centre d'Etude Des Pathologies Respiratoires (CEPR) INSERM U1100, Université de Tours, Tours, France.

Emmanuel Canet (E)

Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire Hôtel-Dieu, 30 Bd. Jean Monnet, 44093, Nantes Cedex 1, France.

Alexandre Boyer (A)

Médecine Intensive Réanimation, Hôpital Pellegrin, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.

Saad Nseir (S)

Médecine Intensive-Réanimation, CHU de Lille; Inserm U1285, Univ. Lille, CNRS, UMR 8576-UGSF-Unité de Glycobiologie Structurale et Fonctionnelle, 59000, Lille, France.

Fabienne Tamion (F)

Médecine Intensive Réanimation, Hôpital Charles Nicolle, Centre Hospitalier Universitaire de Rouen, Rouen, France.

Arnaud W Thille (AW)

Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.

Laurent Argaud (L)

Médecine Intensive Réanimation, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.

Emmanuel Pontis (E)

Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, Rennes, France.

Jean-Pierre Quenot (JP)

Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Dijon, Dijon, France.

Francis Schneider (F)

Médecine Intensive Réanimation, Hôpital de Hautepierre, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France.

Arnaud Hot (A)

Médecine Intensive Réanimation, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France.

Gilles Capellier (G)

Médecine Intensive Réanimation, Centre Hospitalier Régional Universitaire de Besançon, Besançon, France.

Cécile Aubron (C)

Réanimation Médicale, Hôpital de la Cavale Blanche, Centre Hospitalier Régional Universitaire de Bretagne Occidentale, Brest, France.

Keyvan Razazi (K)

Médecine Intensive Réanimation, Hôpital Henri Mondor, Assistance Publique des Hôpitaux de Paris, Créteil, France.

Agathe Masseau (A)

Médecine Interne, Centre Hospitalier Universitaire Nantes, Nantes, France.

Noëlle Brule (N)

Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire Hôtel-Dieu, 30 Bd. Jean Monnet, 44093, Nantes Cedex 1, France.

Jean Reignier (J)

Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire Hôtel-Dieu, 30 Bd. Jean Monnet, 44093, Nantes Cedex 1, France.

Jean-Baptiste Lascarrou (JB)

Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire Hôtel-Dieu, 30 Bd. Jean Monnet, 44093, Nantes Cedex 1, France. jeanbaptiste.lascarrou@chu-nantes.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH